Company UpdateApr 9, 2026, 05:07 PM
Jaguar Health Estimates Stockholders' Equity Reaches $8.3M, Resolving Nasdaq Non-Compliance
AI Summary
Jaguar Health, Inc. (JAGX) announced that it expects to have resolved its non-compliance with Nasdaq Listing Rule 5550(b)(1), which requires a minimum of $2.5 million in stockholders' equity. The company, which reported a stockholders' deficit of approximately $18.7 million as of December 31, 2025, estimates its current stockholders' equity to be approximately $8.3 million. This significant improvement is attributed to a series of capital inflows and gains totaling an estimated $27.0 million since the end of 2025, including non-dilutive capital from a license agreement and debt extinguishment. This development is crucial for Jaguar Health to maintain its listing on The Nasdaq Stock Market.
Key Highlights
- Jaguar Health reported a stockholders' deficit of approximately $18.7 million as of December 31, 2025, falling short of Nasdaq's $2.5 million equity requirement.
- The company estimates its current stockholders' equity to be approximately $8.3 million, exceeding the Nasdaq minimum.
- This improvement includes $16.0 million in non-dilutive capital from a license agreement with Woodward Specialty LLC and Future Pak, LLC.
- An additional $3.0 million was received following the termination of a buy-back provision under the License Agreement.
- The company also recognized a gain of approximately $3.4 million from the extinguishment of part of its debts.
- Further contributions include approximately $1.0 million from product inventory sales, $2.0 million to be received upon satisfaction of Third Party Replacement MSA Conditions, and $1.2 million from Mytesi product sales via a firm order.